Business Context and Reporting Period
This Form 8-K is a current report filed by Tokai Pharmaceuticals, Inc. (Tokai) on February 3, 2017, regarding events occurring on January 31, 2017. The filing details a material definitive agreement entered into to facilitate the acquisition of Otic Pharma, Ltd. (Otic), a private Israeli company. The transaction is expected to close in the first half of 2017, subject to customary conditions.
Key Financial Metrics and Transaction Details
- Capital Raise: Tokai entered into a Stock Purchase Agreement to sell 3,603,601 shares of common stock to certain purchasers.
- Transaction Value: The sale is valued at approximately $4,000,000.
- Share Price: The purchase price is $1.11 per share.
- Total Investment Commitment: The purchasers agreed to invest up to $7,000,000 in Otic and/or Tokai. The remaining $3,000,000 is to be invested in Otic prior to closing via the exercise of outstanding warrants.
- Financial Statements: This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics for Tokai or Otic.
Material Changes and Transaction Structure
The filing discloses a significant change in Tokai's capital structure and strategic direction through the proposed acquisition of Otic. The transaction is structured as follows:
- Acquisition Agreement: Based on a share purchase agreement dated December 21, 2016, Tokai agreed to purchase all ordinary and preferred shares of Otic from its selling shareholders.
- Financing: The $4,000,000 equity raise is a condition precedent to the closing of the Otic acquisition.
- Registration Rights: Upon closing, Tokai will file a Form S-3 registration statement within 45 days to register the newly issued shares, aiming for effectiveness within 120 days to allow for free trading.
- Unregistered Sale: The shares are being sold under exemptions from registration (Section 4(a)(2), Regulation D, and/or Regulation S).
Guidance, Outlook, and Risks
- Outlook: Management expects the transaction to close during the first half of 2017.
- Shareholder Approval: Tokai intends to file a definitive proxy statement (Schedule 14A) to seek stockholder approval for the issuance of shares in the transaction and potentially for a reverse stock split.
- Risks and Contingencies: The transaction is subject to specified closing conditions. The filing includes standard disclaimers that representations and warranties in the agreement are for risk allocation and should not be relied upon as characterizations of actual facts.
- Unusual Items: The filing notes that the Stock Purchase Agreement and Registration Rights Agreement are included for informational purposes and do not provide factual information about the companies beyond the terms of the agreements.
Investor Verification Checklist
- Verify the final closing date of the Otic acquisition, as it is currently projected for the first half of 2017.
- Review the upcoming definitive proxy statement (Schedule 14A) for details on the proposed reverse stock split and the specific terms of the Otic acquisition.
- Confirm the status of the $3,000,000 warrant exercise by purchasers in Otic prior to the transaction closing.
- Monitor the filing and effectiveness of the Form S-3 registration statement for the newly issued shares.
- Assess the financial impact of the acquisition on Tokai's balance sheet once the transaction closes and audited financials for Otic are disclosed.